The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1
Abstract
MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Recently, small-molecule antagonists of MDM2, the Nutlins, have been developed to inhibit the p53-MDM2 interaction and activate p53 signaling. However, half of human cancers have mutated p53 and they are resistant to Nutlin treatment. Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Nutlin-3a also increased the cytotoxicity of both carboplatin and doxorubicin in a series of p53-mutant human tumor cell lines. In the human dedifferentiated liposarcoma cell line (LS141) and the p53 wild-type HCT116 cells, Nutlin-3a induced downregulation of E2F1 and this effect appeared to be proteasome dependent. In contrast, in MPNST and HCTp53-/- cells, Nutlin-3a inhibited the binding of E2F1 to MDM2 and induced transcriptional activation of free E2F1 in the presence of Cis-induced DNA damage. Downregulation of E2F1 by small interfering RNA significantly decreased the level of apoptosis induced by Cis and Nutlin-3a treatment. Moreover, expression of a dominant-negative form of E2F1 rescued cells from apoptosis, whereas cells overexpressing wild-type E2F1 showed an increase in cell death. This correlated with the induction of the proapoptotic proteins p73alpha and Noxa, which are both regulated by E2F1. These results indicate that antagonism of MDM2 by Nutlin-3a in cells with mutant p53 enhances chemosensitivity in an E2F1-dependent manner. Nutlin-3a therefore may provide a therapeutic benefit in tumors with mutant p53 provided it is combined with chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although it has been shown that nutlin3a and other MDM2 PPI inhibitors have single-agent activity in inhibiting the growth of a variety of tumor types including GBM”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [2]
In the citing paper
“The MDM2 protein–protein interaction (PPI) inhibitor nutlin3a binds to the N-terminal hydrophobic pocket of MDM2 and blocks interaction of MDM2 with not only p53 but also a number of other key signal transducers, including p73α, E2F1, Rb, and HIF-1α”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [2]
In the citing paper
“Nutlin-3a also inhibits the binding of the p73 isoform p73α, as well as E2F1 and hypoxia inducible factor 1α (Hif-1α), to the N-terminal hydrophobic pocket of Mdm2 (11–13).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [11]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citationThe MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Expression of transcription factor E2F1 induces quiescent cells to enter S phase
Johnson, D. G., Schwarz, J. K., Cress, W. D., & Nevins, J. R. (1993) · Nature · doi:10.1038/365349a0 · Cited by 943
p53 and E2F-1 cooperate to mediate apoptosis.
Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 840
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
Qin, X. Q., Livingston, D. M., Kaelin, W. G., & Adams, P. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10918 · Cited by 753
Müller, H., Bracken, A. P., Vernell, R., Moroni, M. C., Christians, F. C., Grassilli, E., Prosperini, E., Vigo, E., Oliner, J. D., & Helin, K. (2001) · Genes & Development · doi:10.1101/gad.864201 · Cited by 752
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M. S., Marín, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Self-citationInteraction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586
Research works printed but not linked: 1
- Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR . (1998). Role of E2F1 in chemosensitivity. Cancer Res 58: 4292–4296.
Cited by
Sorted by citations
Items 101–165 of 165
Bertin-Ciftci, J., Barré, B., Pen, J. L., Maillet, L., Couriaud, C., Juin, P. P., & Braun, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.6 · Cited by 23
The Tumor Suppressor Maspin Mediates E2F1-Induced Sensitivity of Cancer Cells to Chemotherapy
Shachar, B. B., Feldstein, O., Hacohen, D., & Ginsberg, D. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0137 · Cited by 23
The Scandinavian Sarcoma Group
Alvegård, T. A., Hall, K. S., Bauer, H. C. F., & Rydholm, A. (2009) · Acta Orthopaedica · doi:10.1080/17453690610046602 · Cited by 23
Disarming mutant p53 oncogenic function
Girardini, J. E., Marotta, C., & Sal, G. D. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.003 · Cited by 23
Michaelis, M., Rothweiler, F., Agha, B., Barth, S., Voges, Y., Löschmann, N., von Deimling, A., Rainer Breitling, A., Doerr, H. W., Rödel, F., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.35 · Cited by 22
Pharmacological therapies for Liposarcoma
Saponara, M., Stacchiotti, S., & Gronchi, A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1289086 · Cited by 22
The ubiquitin-proteasome system in the regulation of tumor dormancy and recurrence
Alhasan, B. A., Morozov, A. V., Guzhova, I. V., & Margulis, B. A. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189119 · Cited by 20
Ma, T., Yamada, S., Ichwan, S. J. A., Iseki, S., Ohtani, K., Otsu, M., & Ikeda, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.161 · Cited by 19
Sulg, M., Kirjavainen, A., Pajusola, K., Büeler, H., Ylikoski, J. S., Laiho, M., & Pirvola, U. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06563.x · Cited by 19
SRSF2 Regulation of MDM2 Reveals Splicing as a Therapeutic Vulnerability of the p53 Pathway
Comiskey, D. F., Montes, M., Khurshid, S., Singh, R. K., & Chandler, D. S. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0541 · Cited by 19
The TP73 complex network: Ready for clinical translation in cancer?
Soldevilla, B., Millán, C. S., Bonilla, F., & Domínguez, G. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22095 · Cited by 18
Senturk, J. C., Bohlman, S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.229 · Cited by 20
Recent translational research into targeted therapy for liposarcoma
Patel, R. B., Li, T., Liao, Z., Jaldeepbhai, J. A., Perera, H. A. P. N. V., Muthukuda, S. K., Dhirubhai, D. H., Singh, V. P., Du, X., & Yang, J. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.02.09 · Cited by 17
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 17
Shuvalov, O. Y., Kizenko, A., Shakirova, A., Fedorova, O., Petukhov, A., Aksenov, N. D., Vasileva, E., Daks, A. A., & Barlev, N. A. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.118 · Cited by 17
Putri, H. E., Nutho, B., Rungrotmongkol, T., Sritularak, B., Vinayanuwattikun, C., & Pithi Chanvorachote, B. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153534 · Cited by 17
Matsuya, Y., McMahon, S. J., Ghita, M., Yoshii, Y., Sato, T., Date, H., & Prise, K. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45960-z · Cited by 17
Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation
Suleymanova, N., Crudden, C., Worrall, C., Dricu, A., Girnita, A., & Girnita, L. (2017) · Oncotarget · doi:10.18632/oncotarget.19286 · Cited by 15
ATP stimulates MDM2‐mediated inhibition of the DNA‐binding function of E2F1
Stevens, C., Pettersson, S., Wawrzynów, B., Wallace, M., Ball, K. L., Żylicz, M., & Hupp, T. R. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06627.x · Cited by 15
Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication
Ehrenfeld, M., Segeth, F., Mantwill, K., Brockhaus, C., Zhao, Y., Ploner, C., Kolk, A., Gschwend, J. E., Nawroth, R., & Holm, P. S. (2023) · Journal of Virology · doi:10.1128/jvi.00370-23 · Cited by 14
Ye, D.-J., Kwon, Y., Baek, H., Cho, E.-A., Kwon, T.-U., & Chun, Y. (2019) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2019.1635934 · Cited by 13
Huart, A.-S., SAXTY, B. A., Merritt, A. T., Nekulová, M., Lewis, S., Huang, Y., Vojtěšek, B., Kettleborough, C. A., & Hupp, T. R. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.046 · Cited by 14
Gene Translocations in Musculoskeletal Neoplasms
Krishnan, B., Khanna, G., & Clohisy, D. R. (2008) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-008-0342-0 · Cited by 13
Nadler-Milbauer, M., Apter, L., Haupt, Y., Haupt, S., Barenholz, Y., Minko, T., & Rubinstein, A. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2011.622401 · Cited by 12
Molecular characteristics and systemic treatment options of liposarcoma: A systematic review
Zhou, X.-P., Xing, J., Sun, L.-B., Tian, S.-Q., Luo, R., Liu, W., Song, X.-Y., & Gao, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117204 · Cited by 12
de Camargo, V. P., van de Rijn, M., de Álava, E., Madoz‐Gúrpide, J., Pilotti, S., von Mehren, M., Pédeutour, F., Maki, R. G., Rutkowski, P. L., & Thomas, D. M. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.06.008 · Cited by 11
Biswas, S., Killick, E., Jochemsen, A. G., & Lunec, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892924 · Cited by 11
Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
Wu, L., Hu, Y., He, Y., Xia, Y., Lu, H., Cao, Z. Y., Yi, X., & Wang, J. (2019) · The Analyst · doi:10.1039/c9an00301k · Cited by 9
Zhang, L., Yan, Y., Zhu, D., Yang, W., Wang, W., Hu, Y., Yang, B., & He, Q. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9512-5 · Cited by 8
Wu, L., Yang, Y., Wang, Z., Wu, X., Su, F., Li, M., Jing, X., & Han, C. (2020) · Molecules · doi:10.3390/molecules25051162 · Cited by 8
Yang, Z.-H., Zhou, C., Zhu, H., Li, J., & He, C. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.8.3817 · Cited by 7
Targeting MDM2 affects spastin protein levels and functions: implications for HSP treatment
Sardina, F., Polverino, F., Valentini, S., Carsetti, C., Falvo, E., Tisci, G., Soddu, S., Moretti, F., Paiardini, A., & Rinaldo, C. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02333-y · Cited by 3
Fuentes, M., Srivastava, S., Gronenborn, A. M., & LaBaer, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010053 · Cited by 3
p53-Reactivating Molecules as Research Tools and Anticancer Drugs
Grinkevich, V. V., Warnecke, A., & Selivanova, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_13 · Cited by 2
Singhi, A. D., & Montgomery, E. A. (2011) · Surgical pathology clinics · doi:10.1016/j.path.2011.08.011 · Cited by 2
Laurino, L., & Tos, A. P. D. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4160-5455-9.00012-0 · Cited by 2
Mechanisms and Ways to Overcome Acquired Resistance of Cancer Cells to Mcl-1 Antagonists
Pervushin, N. V., Fernandez, B. Y. V., Senichkin, V. V., Yapryntseva, M. A., Pavlov, V., Zhivotovsky, B., & Kopeina, G. S. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297925602710 · Cited by 1
p53, p63 and p73 Network in Breast Cancers
Leong, C. (2011) · InTech eBooks · doi:10.5772/20337 · Cited by 1
Sbaraglia, M., & Tos, A. P. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-49714-5.00012-0 · Cited by 1
Hydrogen Peroxide induces resistance to DNA damage in a localization and p53 dependent mannerPreprint
Keijer, J. P., Polderman, P. E., Alcaraz, P. S., van Es, R. M., González, D. M., Kok, R. N. U., Baghdadi, S. E., Gulersonmez, C. M. C., Stigter, E. C. A., Vos, H. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724825 · Cited by 1
E2F1 induction following DNA damage and oncogene activation
Helgason, G. V. (2007) · Enlighten: Theses (The University of Glasgow)
IKKalpha mediated NOTCH1 Activation Promotes Tumorigenesis via FOXA2 Suppression
Liu, M. (2012) · Digital Commons-TMC (Texas Medical Center)
Molecular analysis of the domain with no name (DWNN)/RBBP6 in human cancers
Mbita, Z. (2012) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Modulation of the Mdm2 signaling axis sensitizes triple-negative breast cancer cells to carboplatin
Tonsing-Carter, E. Y. (2014) · ProQuest Demo Repository · doi:10.7912/c2/308
Nomenjanahary, C. E. (2013) · Lu Zone Ul (Laurentian University)
MEK inhibition in pancreas cancer
Vena, F. (2016) · UCL Discovery (University College London)
Investigation of the intrinsic mechanism of drug resistance in multiple myeloma
Ooi, M. G. M. (2011) · Dublin City University Open Access Institutional Repository (Dublin City University)
Tos, A. P. D. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316535097.009
Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., Nagashima, M., Takenoshita, S., Yokota, J., & Harris, C. C. (2023) · doi:10.1158/0008-5472.c.6497172
Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., Nagashima, M., Takenoshita, S., Yokota, J., & Harris, C. C. (2023) · doi:10.1158/0008-5472.c.6497172.v1
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2023) · doi:10.1158/1535-7163.c.6532173
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2023) · doi:10.1158/1535-7163.c.6532173.v1
Jones, R. J., Chen, Q., Voorhees, P. M., Young, K. H., Bruey-Sédano, N., Yang, D., & Orlowski, R. Z. (2023) · doi:10.1158/1078-0432.c.6516888
Putri, H. E., & Pithi Chanvorachote, B. (2021) · Chula Digiverse · doi:10.58837/chula.the.2021.314
Molecular Therapy for Rhabdomyosarcoma
Kurmasheva, R. T., Hosoi, H., Kikuchi, K., & Houghton, P. J. (2010) · Springer eBooks · doi:10.1007/978-0-387-69062-9_20
Villalonga-Planells, R. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Rôle des mastocytes dans le développement des astrocytomes humains : implication du récepteur CD47
Boukhari, A. A. (2012) · theses.fr (ABES) · doi:10.70675/3c922fc3z5510z47b6zba8ezeb4143cfb7ba
Nuclear Receptor Property of E2F1 for Novel Anticancer Drug Discovery
Zhang, N., Li, J., & Meng, A. (2013) · Lecture notes in electrical engineering · doi:10.1007/978-3-642-37922-2_85
Modulation of apoptosis and signalling in cancer cells after treatment with epigenetic modulators
Palani, R. N., & Devi, C. P. A. (2012) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
Metadata
- Authors
- Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Schwartz, G K
- Venue
- Oncogene
- Published
- 2006-12-04
- Volume
- 26
- Issue
- 24
- Pages
- 3473-3481
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2003463790
- Cited by
- 163
- References
- 38
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 7 · 2018: 1 · 2017: 8 · 2016: 5 · 2015: 6 · 2014: 13 · 2013: 11 · 2012: 15
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- Nutlin-3a, MDM2 inhibitors, mutant p53, E2F1, chemotherapy-induced apoptosis, cisplatin, chemosensitization, malignant peripheral nerve sheath tumor, liposarcoma, p73alpha, Noxa, proteasomal degradation, p53-MDM2 interaction, doxorubicin, carboplatin
- MeSH terms
- Tumor Protein p73, Animals, Antineoplastic Agents, Cisplatin, DNA-Binding Proteins, Doxorubicin, Humans, Imidazoles, Nuclear Proteins, Piperazines, Transcription, Genetic, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Carboplatin, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Tumor Suppressor Proteins, E2F1 Transcription Factor, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
